Nanoscale imaging of pT217‐tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early‐stage neurodegeneration
Authors:
- Dibyadeep DattaDibyadeep Datta
- Isabella PeroneIPIsabella Perone
- Denethi WijegunawardanaDWDenethi Wijegunawardana
- Feng LiangFLFeng Liang
- Yury M. MorozovYury M. Morozov
- Jon ArellanoJAJon Arellano
- Alvaro DuqueADAlvaro Duque
- Zhongcong XieZXZhongcong Xie
- Christopher H. van DyckCDChristopher H. van Dyck
- Mary Kate P. JoyceMJMary Kate P. Joyce
- Amy F. T. ArnstenAAAmy F. T. Arnsten
Open Access
- 6 March 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (4) , 2843-2860
Abstract
INTRODUCTION: Tau phosphorylated at threonine‐217 (pT217‐tau) is a novel fluid‐based biomarker that predicts onset of Alzheimer's disease (AD) symptoms, but little is known about how pT217‐tau arises in the brain, as soluble pT217‐tau is dephosphorylated post mortem in humans.METHODS: We used multilabel immunofluorescence and immunoelectron microscopy to examine the subcellular localization of early‐stage pT217‐tau in entorhinal and prefrontal cortices of aged macaques with naturally occurring tau pathology and assayed pT217‐tau levels in plasma.RESULTS: pT217‐tau was aggregated on microtubules within dendrites exhibiting early signs of degeneration, including autophagic vacuoles. It was also seen trafficking between excitatory neurons within synapses on spines, where it was exposed to the extracellular space, and thus accessible to cerebrospinal fluid (CSF)/blood. Plasma pT217‐tau levels increased across the age span and thus can serve as a biomarker in macaques.DISCUSSION: These data help to explain why pT217‐tau predicts degeneration in AD and how it gains access to CSF and plasma to serve as a fluid biomarker.Keywords
All Related Versions
This publication has 75 references indexed in Scilit:
- Blood tau‐PT217 contributes to the anesthesia/surgery‐induced delirium‐like behavior in aged miceAlzheimer's & Dementia, 2023
- Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma BiomarkersJAMA Neurology, 2023
- Localization, induction, and cellular effects of tau phosphorylated at threonine 2171Alzheimer's & Dementia, 2023
- Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primatesAlzheimer's & Dementia, 2021
- Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker researchAlzheimer's & Dementia, 2021
- Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer DiseaseJAMA Neurology, 2021
- Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosisAlzheimer's & Dementia, 2020
- Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's diseaseAlzheimer's & Dementia, 2020
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- Prologue2014